Men with advanced and metastatic prostate cancer are not cured by standard treatments. Radioligand Therapy (RLT) targeting PSMA, an abnormal protein found in prostate cancers, is a promising treatment for cancer survivors with prostate cancer that has become unresponsive to endocrine treatments. This national program will address the practical issues of making and distributing the radioactive drugs used for diagnosis and treatment, build up the infrastructure to deliver the treatment, and improve upon the efficacy of RLT.
The CanSURVIVE Research Group is providing economic evidence to show the potential value, through an economic lens, of RLT for prostate cancer. The evidence provided could also demonstrate how early-stage health technology assessment methods can inform decisions on resource allocation and product development including future study design to support the treatment.
Co-Principal Investigators: Stuart Peacock, BC Cancer, Simon Fraser University; Kelvin Chan, Sunnybrook Odette Cancer Centre, University of Toronto; Winson Cheung, University of Calgary; Scott Gavura, Ontario Health; J Irish; M Tadrous
Principal Investigators: Dr. Renelle Myers, Vancouver General Hospital, University of British Columbia, BC Cancer; Dr. Rayjean Hung, Mount Sinai Hospital, University of Toronto
Principal Investigator: Steven Gallinger, Princess Margaret Cancer Centre, University of Toronto
Co-Principal Investigators: Stuart Peacock, BC Cancer, Simon Fraser University; Francois Bernard, BC Cancer, University of British Columbia; J Valliant; F Prato, W Isaranu-watchai, F Wuest, J Beauregard, K Zukotynski, K Chi, F Saad